14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CURE vs NAIL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CURE Overall Winner
6-Pillar Tally: CURE 1 – 0 NAIL (5 Tie)
Matrix Metrics: CURE 2 – 1 NAIL
As of Nov 16, 2026, Direxion Daily Healthcare Bull 3X Shares (CURE) is the stronger overall head-to-head candidate over Direxion Daily Homebuilders & Supplies Bull 3X Shares (NAIL) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Options & Positioning). CURE carries a Unified Composite Score of 38.6/100 (SELL) at $174.60 (N/M Forward P/E, N/A operating margin), whereas NAIL carries 48.8/100 (HOLD) at $32.48 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While NAIL currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. CURE 38.6/100 SELL), CURE captures the overall institutional head-to-head verdict (2–1 matrix metrics and 1–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Technical & Structure Timing Caution: CURE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.6); meanwhile NAIL is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CURE vs NAIL. Trailing 12-month operating profitability (CURE N/A vs NAIL N/A) and valuation multiples (CURE N/M vs NAIL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
NAIL Moat ProfileCyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CURE vs NAIL Key Questions & Quantitative Answers
As of Nov 16, 2026, Direxion Daily Healthcare Bull 3X Shares (CURE) is the stronger overall head-to-head candidate over Direxion Daily Homebuilders & Supplies Bull 3X Shares (NAIL) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Options & Positioning). CURE carries a Unified Composite Score of 38.6/100 (SELL) at $174.60 (N/M Forward P/E, N/A operating margin), whereas NAIL carries 48.8/100 (HOLD) at $32.48 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While NAIL currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. CURE 38.6/100 SELL), CURE captures the overall institutional head-to-head verdict (2–1 matrix metrics and 1–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: CURE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.6); meanwhile NAIL is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CURE and NAIL split Growth & Scale metrics: CURE posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with NAIL at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CURE generates N/A in USD-normalized revenue versus N/A for NAIL. In operating R&D and SG&A reinvestment, CURE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NAIL.
CURE and NAIL trade at balanced relative valuation multiples. CURE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NAIL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CURE (N/A ROE) versus NAIL (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, CURE carries 45.1% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.83β · 62% Vol realized risk). By comparison, NAIL carries 115.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.33x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.84β · 137% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.